ArticleJCO global oncology2024
Erratum: Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.